Consecutive Dual-Session tDCS in Chronic Subjective Severe to Catastrophic Tinnitus With Normal Hearing
1 other identifier
interventional
42
1 country
1
Brief Summary
We aimed to analyze the effect of continuous dual session tDCS in patients with severe chronic subjective tinnitus without any evidence of hearing loss in terms of relief of tinnitus perception, distress, and loudness. Also, we investigated the difference in the maintenance duration of the tinnitus suppression effect of consecutive dual session tDCS compared to other groups followed up for 2 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2021
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
September 30, 2022
CompletedFirst Submitted
Initial submission to the registry
May 16, 2024
CompletedFirst Posted
Study publicly available on registry
May 21, 2024
CompletedMay 21, 2024
May 1, 2024
10 months
May 16, 2024
May 16, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Visual analogue scale (VAS) related to tinnitus
To achieve a more quantitative evaluation of tinnitus reduction, we assessed the Visual Analog Scale (VAS).
All participants were checked the VAS immediately after the last stimulation of every week for 4 weeks and 8th week (4 weeks after the end of treatment).
Tinnitus Handicap Inventory (THI)
The subjective improvement of tinnitus was evaluated using THI.
THI was assessed at the 4th and 8th week visits.
Beck depression inventory (BDI)
To assess the association between tinnitus relief and depression, we evaluated the Beck Depression Inventory (BDI).
THI was assessed at the 4th and 8th week visits.
Study Arms (3)
control
SHAM COMPARATORThe subjects in control group were received two consecutive sessions of sham stimulation twice a week for 4 weeks (8 sessions in total).
single-session
ACTIVE COMPARATORPatients enrolled to the single-session group received tDCS on one random session out of two consecutive sessions.
dual-session
EXPERIMENTALIn the dual-session group, the patients underwent two consecutives tDCS.
Interventions
The device used for tDCS in this study was DC-Stimulator Plus (NeuroConn GmbH, Ilmenau, Germany). The localization of stimulation area (DLPFC) was determined according to the 10/20 EEG system. Non-conducting, elastic head strap was placed around the head to prevent displacement during stimulation. The recording electrode covered with 5 x 7 cm sized traditional rectangular sponge was soaked with 6-7 mL of 0.9% NaCl saline solution per side and placed on the F3 (anode, left frontal) and F4 (cathode, right frontal) EEG location. Subjects were given 2 mA stimulation intensity for 20 min per session including fade-in and fade-out times for 20 seconds each. Interval between each session was 20 min. Sham procedure has been adopted a Fade In of current, Short Stimulation, Fade Out (FISSFO) protocol that consist of initial ramp up for 20 seconds, 2 mA stimulation for 40 seconds, and 20 seconds for ramp down. To check to impendence, brief current of 110 µA over 15ms every 550ms was delivered.
Eligibility Criteria
You may qualify if:
- Individuals who have experienced subjective tinnitus for over 3 months.
- Individuals with normal hearing, defined as an average pure tone threshold of less than 25 dB between 0.5-4 kHz, and the presence of the V wave at 30 dBnHL with a difference in V wave latency of less than 0.2 ms in both ears during the ABR test.
- Individuals with severe tinnitus, as indicated by a Tinnitus Handicap Inventory (THI) score of 58 or higher, and who have been assessed for symptoms of anxiety and depressive mood using the Beck Depression Inventory (BDI) questionnaire.
You may not qualify if:
- Those requiring treatment for neurological disorders such as epilepsy, migraine, or intracranial masses.
- Pregnant individuals on the day of providing consent and those with metal-based electric implantable prosthetics.
- Individuals with objective or somatic tinnitus, auditory hallucinations, unwillingness to provide written consent, or unwillingness to continue the trial, and those who have participated in previous trials involving tDCS for tinnitus.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Dongtan Sacred Heart Hospital
Hwaseong-si, Gyeonggi-do, 445-170, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Sung Kyun Kim
University of Michigan
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 16, 2024
First Posted
May 21, 2024
Study Start
December 15, 2021
Primary Completion
September 30, 2022
Study Completion
September 30, 2022
Last Updated
May 21, 2024
Record last verified: 2024-05